Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer – ESMO Open

ESMO Open shared a post on X:

“Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer in ESMO Open. 101 patients with solid tumors, ORR 77%, mDOR and mPFS 59 and 61 months, respectively. 88% of patients with TRAES, 26% of G3 or higher.”

Title: Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

Authors: D.S. Hong, R.-H. Xu, L. Shen, M.P. Dierselhuis, D. Orbach, R. McDermott, A. Italiano, M. Tahara, V. Bernard-Gauthier, N. Neu, C.E. Mussi, E. De La Cuesta, T.W. Laetsch, A. Drilon

Read the Full Article.

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer - ESMO Open

Insight

A. Drilon A. Italiano C.E. Mussi cancer D. Orbach D.S. Hong E. De La Cuesta ESMO Open L. Shen M. Tahara M.P. Dierselhuis N. Neu OncoDaily Oncology R. McDermott R.-H. Xu T.W. Laetsch V. Bernard-Gauthier

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer – ESMO Open

“Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer in ESMO Open. 101 patients with solid tumors, ORR 77%, mDOR and mPFS 59 and 61 months, respectively. 88% of patients with TRAES, 26% of G3 or higher.”